Cathie Wood Just Spent $20M On Meta — Here’s Why She’s Selling AMD

ARK Invest snapped up $20.5 million in Meta Platforms stock, signaling a bullish stance on the company's AI roadmap.

image.png
Source

Cathie Wood’s ARK Invest made a series of portfolio moves on Thursday, July 9, 2026. The biggest trade of the day was a $20.55 million purchase of Meta Platforms stock through the ARK Innovation ETF (ARKK).

Screenshot_10-7-2026_161856_coincentral.com.jpeg

Meta Platforms, Inc., META

ARK bought 34,080 shares of Meta. The move came just weeks before Meta is set to report its second-quarter earnings on July 29.

Wall Street expects Meta to post earnings per share of $7.17 on revenue of $60.19 billion for the quarter.

ARK Buys Into Meta’s AI Push

The purchase followed a string of AI-related announcements from Meta. The company launched Muse Spark 1.1, its first paid AI model, and unveiled new AI tools for businesses.

Meta also said its in-house AI chip, Iris, is set for mass production in September. The company announced plans to invest more than $13 billion in a new data center in Alberta, Canada.

On TipRanks, Meta holds a Strong Buy consensus rating based on 34 Buy ratings and five Hold ratings. The average price target of $817.15 points to roughly 29.4% upside from current levels. Meta shares are down 4.2% year-to-date.

ARK Trims AMD and Other Holdings

On the sell side, ARK offloaded 10,774 shares of Advanced Micro Devices through its ARKK ETF. The sale was worth $5.57 million. This is part of a broader pullback in AMD, with ARK reducing its position over the past week.

ARK also sold 85,319 shares of Robinhood Markets (HOOD) for $9.69 million and 70,154 shares of Roku (ROKU) for $9.77 million.

Shares of Twist Bioscience (TWST) were also trimmed, with ARK selling 98,776 shares for $8.83 million.

Beyond Meta, ARK added to its position in Circle Internet Group. It bought 217,896 shares across its ARKK, ARKW, and ARKF ETFs, totaling $13.96 million.

ARK also picked up 105,364 shares of Ionis Pharmaceuticals (IONS) for $8.9 million and 544,385 shares of Prime Medicine (PRME) for $2.52 million.

Smaller buys included 57,462 shares of Generate Biomedicines for $911,921 and 46,302 shares of Compass Pathways (CMPS) for $646,838.

Meta stock rose 6.58% on July 10, the day after ARK’s purchase was disclosed.

STOCKS IN THIS ARTICLE

Comments